You can be part of the Future of veterinary medicine

NASDAQ: KIN

We love the pets around us – our dogs and cats we share our lives with. Many of us believe these animals are part of the family, providing us unconditional love and companionship throughout our lives. We have an opportunity for cutting edge treatment when disease and chronic conditions cross our path, but what happens when our pets encounter these same issues?

Treatment options for our pets shouldn’t be limited

KindredBio has a deep and innovative pipeline for the veterinary industry

Learn More about Analyst Ratings and Earnings on

Download the Corporate Presentation to learn more about our strategy, team, and programs.

KindredBio-Corporate-Presentation_3.16.2021-Final

Looking for More?

The Management Team

We have a world class leadership team guiding us in our quest to develop the best medicines for our best friends.

See Our Pipeline

KindredBio has an exciting pipeline of high-value products for dogs and cats in development.

NASDAQ: KIN

News

  • Elanco Announces Agreement to Acquire Kindred BiosciencesJune 16, 2021 - 6:57 am
  • Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody for the Prevention of Deaths in Dogs Infected by ParvovirusJune 2, 2021 - 8:45 am
  • Kindred Biosciences to Present at Stifel 2021 Virtual Jaws & Paws Conference and LD Micro Invitational XIMay 25, 2021 - 8:57 am

Events

  • Event: Kindred Biosciences to Present at the LD Micro Invitational XIMay 25, 2021 - 9:14 am
  • Event: Kindred Biosciences to Present at the Stifel 2021 Virtual Jaws & Paws ConferenceMay 25, 2021 - 9:12 am
  • Event: Kindred Biosciences to Announce Fourth Quarter and Full Year 2020 Financial ResultsMarch 8, 2021 - 8:48 am
Contact Us | Careers | Privacy Policy | Website Terms of Use | Forward Looking Statements
© Copyright 2012-2020 | Kindred Biosciences, Inc. | 1555 Bayshore Hwy. Suite 200 Burlingame, CA 94010
Scroll to top